The Global Market for Ion Channel Modulators is Projected to Decline to US$10.6 Billion by 2018
Patent Expiries & Lackluster
Pipeline Restrain Growth in the Ion Channel Modulators Market, According to a
New Report by Global
Industry Analysts, Inc.
GIA
announces the release of a comprehensive global report on Ion Channel
Modulators. The
global market for Ion Channel Modulators is projected to decline to US$10.6
billion by 2018, on account of poor understanding about their complicated
mode of action, impending patent expiries of leading drugs, and lack of
adequate products in the pipeline.
Despite
data provided by the Human Genome Project regarding the use of ion channels as
drug targets and the discovery of channelopathies, the use of ion channel
modulators is limited by their extreme physiological, functional, and
structural diversity, and restricted target validation for drug action. Insufficient
research, patent expiries of branded drugs and generic competition, and
lackluster pipeline are eroding revenue for ion channel modulators. Lyrica (by
Pfizer) and Namenda XR (by Forest Laboratories) represent the leading ion
channel modulators on the market. Though they are protected from generic
competition by extended patents, the overall market situation remains grim. Due
to ion channels’ highly complicated mode of action and inadequate research in
the space, the market is restricted by very few products in the pipeline.
Ion
channel modulators on the market currently include calcium channel blockers,
such as amlodipine, and potassium channel blockers such as carbutamide,
targeted against hypertension and diabetes, respectively. Neuropathic pain
management represents a key therapeutic area because of the significance of ion
channel transport in the nervous system and pain pathways. One of the few
pipeline drugs, in fact, include TV-45070 by Teva Pharmaceuticals that acts
against the novel target Nav1.7 ion channel within the pain transmission
pathway. Initial trials of the drug showed positive results. Other therapeutic
areas with potential include oncology, central nervous system disorders,
epilepsy, among others.
As
stated by the new market research report on Ion Channel Modulators, the United States
represents the largest market, followed by Europe. The country accounts for an
estimated 47.8% of the global market and is projected to shrink at a compounded
annual rate of -3.2% over the analysis period. Likewise, Europe and all other
regions globally are projected to record a negative CAGR.
The
global Ion channel modulator market is led by Pfizer and Forest Labs, the
developers of the top two revenue-grossing products, Lyrica and Namenda,
respectively. The ion channel market is comprised of major pharmaceutical
giants, as well as medium and small sized biotech companies, such as
Convergence Pharmaceuticals Limited and Hydra Biosciences, that mainly focus on
ion channel research and drug development. These small-sized companies enjoy
competitive advantages, owing to their intense focus in the concerned area,
highly skilled teams, as well as focus on libraries of specific compounds for
screening. Consequently, around 65% of the ion channel drugs under development
belong to medium to small-sized companies.
Major
players in the market include AstraZeneca, Bayer HealthCare, CalciMedica Inc.,
Convergence Pharmaceuticals Ltd., Evotec AG, Forest Laboratories LLC,
GlaxoSmithKline Plc., Johnson & Johnson, Lundbeck, Novartis AG, Parion
Sciences Inc., Pfizer Inc., Sanofi, Targacept Inc., and Xention Limited, among
others.
The research report titled “Ion
Channel Modulators: A Global Strategic Business Report” announced by the Global
Industry Analysts Inc., provides a comprehensive review of market trends, issues
and concerns, future prospects, recent industry activity, and profiles of major
and niche global as well as regional market participants. The report provides
market estimates and projections in US$ for all major geographic markets, including
the US,
Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia, and Rest of
Europe), Asia-Pacific (China, India, and Rest of Asia-Pacific), Latin America
(Brazil and Rest of Latin America), and Rest of World.
Comments
Post a Comment